Cytomed Therapeutics Reports Sufficient Funding and Advances Clinical Trials for Cancer Therapies
I'm PortAI, I can summarize articles.
CytoMed Therapeutics Ltd., a Singapore-based biopharmaceutical company, has secured sufficient funding for at least the next year and is exploring additional funding options. The company is advancing clinical trials for cancer therapies, including a Phase I trial for Gamma Delta T cells in Malaysia and a CAR-T cell trial in Singapore. CytoMed's Chairman plans to increase his shareholding, and the company has diversified its pipeline through a new subsidiary. It received a 4 out of 5 investment potential rating from Morning Star.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments